Vela Diagnostics

Vela Diagnostics is a global molecular diagnostics company founded in 2011 and based in Singapore, employing around 200 people worldwide. The company specializes in integrated platforms that utilize real-time PCR and Next-Generation Sequencing (NGS) technologies, offering a wide range of molecular testing solutions for infectious diseases and cancer diagnostics. Vela Diagnostics develops and markets over 30 diagnostic tests across nine disease areas, focusing on oncology and virology, including conditions like melanoma, non-small cell lung cancer, colorectal cancer, and HIV. Their offerings include automated "sample-to-result" workflows, standardized instruments, and open-channel capabilities, which enhance testing flexibility and efficiency. The product suite features real-time PCR assays, NGS panels, data reporting software, and consumables that support molecular diagnostics workflows. With ISO 13485:2003 certified facilities in Singapore and the U.S., and a CLIA-certified laboratory, Vela Diagnostics maintains a strong regulatory framework. The company serves clinical laboratories, hospitals, pharmaceutical companies, and research institutions, and collaborates with academic and industry partners to advance healthcare solutions.

• Employees 91
• Founded 2011
• Annual Revenue $15000000
• Total Funding $225000